Physician profile
Jennifer Roberson
NPI 1043211998
$488.39
in general payments reported to CMS, 2019-2025
12 companies · $82.28 in 2025
The $82.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.66 · 2020: $32.47 · 2021: $35.11 · 2022: $15.80 · 2023: $145 · 2024: $159 · 2025: $82.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171.18 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $68.76 | 2023 | Mounjaro |
| Astellas Pharma US INC | $46.29 | 2024-2025 | Veozah |
| Janssen Scientific Affairs, LLC | $40.60 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $31.43 | 2024 | |
| Abbott Laboratories | $22.81 | 2025 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $20.27 | 2024 | Crysvita |
| Dexcom, INC. | $19.49 | 2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $18.66 | 2019 | |
| Braeburn INC. | $18.21 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $15.80 | 2022 | |
| Amgen INC. | $14.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.